Development and characterization of nanosuspensions of olmesartan medoxomil for bioavailability enhancement

Journal of Pharmacy and Bioallied Sciences

Volumn 3, Issue 3, 2011, Pages 426-434

  Thakkar, Hetal Paresh ^a   Patel, Bindesh Vishnubhai ^a   Thakkar, Sneha Piyush ^a  

^a Pharmacy Department   (India)

Author keywords

Bioavailability; dissolution; nanosuspension; solubility

Indexed keywords

MANNITOL; NANOCRYSTAL; OLMESARTAN; POLOXAMER; SURFACTANT;

AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; CRYOPROTECTION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG DIFFUSION; DRUG PENETRATION; FREEZE DRYING; INTESTINE; PARTICLE SIZE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; STOMACH; TRANSMISSION ELECTRON MICROSCOPY; X RAY DIFFRACTION; ZETA POTENTIAL;

EID: 80052725477     PISSN: None     EISSN: 09757406     Source Type: Journal    
DOI: 10.4103/0975-7406.84459     Document Type: Article

References (24)

1. Merisko-Liversidge E. Nanocrystals: Resolving pharmaceutical formulation issues associated with poorly water-soluble compounds. In: Marty JJ, editor. Particles. Orlando: Marcel Dekker; 2002
2. Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev 2000;45:89-121.
3. Nakano M. Places of emulsions in drug delivery. Adv Drug Deliv Rev 2000;45:1-4.
4. Stella VJ, Rajewski RA. Cyclodextrins: Their future in drug formulation and delivery. Pharm Res 1997;14:556-67. (Pubitemid 27220271)
5. Kesisoglou F, Panmai S, Wu Y. Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev 2007;59:631-44. (Pubitemid 47285408)
6. Kocbek P, Baumgartner S, Kristl J. Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs. Int J Pharm 2006;312:179-86.
7. Liversidge GG, Cundy K. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int J Pharm 1995;125:91-7.
8. Moschwitzer J, Muller RH. Spray coatedpellets as carrier systemformucoadhesive drug nanocrystals. Eur J Pharm Biopharm 2006;62:282-7. (Pubitemid 43356577)
9. Trotta M, Gallarate M, Carlotti ME, Morel S. Preparation of griseofulvin nanoparticles fromwater-dilutable microemulsions. Int J Pharm 2003;254:235-42. (Pubitemid 36298832)
10. Keck CM, Muller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenization. Eur J Pharm Biopharm 2006;62:3-16. (Pubitemid 41736019)
11. Rabinow BE. Nanosuspensions in drug delivery. Nature 2004;3:785-93.
12. Merisko-Liversidge E, Liversidge GG, Cooper ER. Nanosizing: A formulation approach for poorly-water-soluble compounds. Eur J Pharm Sci 2003;18:113-20. (Pubitemid 36184748)
13. Muller RH, Becker R, Kruss B, Peters K. Pharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution. United States Patent 5,858,410, USA, 1999.
14. Jacobs C, Kayser O, Muller RH. Nanosuspensions as a new approach for the formulation for the poorly soluble drug tarazepide. Int J Pharm 2000;196:161-4. (Pubitemid 30105734)
15. Warne GT, Jarvis B. Olmesartan medoxomil. Drugs 2002;62:1345-53. (Pubitemid 34800096)
16. Bruner HR, Nussberger J. Relevance of clinical pharmacological models for the evaluation of therapeutic dose range of an AT1-receptor antagonist. J Hypertens 2001;19:15-20.
17. Neutel JM, Elliott WJ, Izzo JL, Chen CL, Masonson HN. Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, as assessed by ambulatory blood pressure measurements. J Clin Hypertens 2002;5:325-31. (Pubitemid 35214724)
18. www.drugbank.ca/olmesartan medoxomil
19. Van Eerdenbrugh B, Froyen L, Martens JA, Blaton N, Augustijns P, Brewster M, et al. Characterization of Physico-chemical properties and pharmaceutical performance of sucrose co-freeze-dried solid Nanoparticulate powders of the anti-HIV agent loviride Prepared by media milling. Int J Pharm 2007;338:198-206. (Pubitemid 46779149)
20. Bhavsar MD, Tiwari SB, Amiji MM. Formulation optimization for the nanoparticles-in-microsphere hybrid oral delivery system using factorial design. J Control Release 2006;110:422-30. (Pubitemid 41827496)
21. Armstrong NC, James KC. Pharmaceutical experimental design and interpretation. Bristol, PA, USA: Taylor and Francis Publications; 1996, 131-92.
22. Möschwitzer J, Achleitner G, Pomper H, Müller RH. Development of an intravenously injectable chemically stable aqueous omeprazole formulation using nanosuspension technology. Eur J Pharm Biopharm 2004;58:615-9. (Pubitemid 39297108)
23. Müller RH, Jacobs C, Kayser O. Nanosuspension as particulate drug formulations in therapy rationale for development and what we can expect for the future. Adv Drug Deliv Rev 2001;47:3-19. (Pubitemid 32209229)
24. Lindenberg M, Knopp S, Dressman JB. Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm 2004;58:265-78. (Pubitemid 39037234)